Abstract: Recently, 3 oral Janus kinase (JAK) inhibitors—abrocitinib, baricitinib, and upadacitinib—were approved in many regions around the world for the treatment of moderate–severe atopic dermatitis (AD). These JAK inhibitors generally have rapid onset of action and short half-life. Higher doses of abrocitinib and upadactinib even demonstrated superior efficacy to dupilumab. However, JAK inhibitors can be associated with rare serious and potentially life-threatening adverse events. Heterogeneity in study designs and lack of head-to-head studies make safety comparison between JAK inhibitors difficult. Dose reduction and patient selection are the most important considerations for risk mitigation. This narrative review examines the efficacy data for abrocitinib, baricitinib, and upadacitinib from large phase III double-blinded randomized controlled trials in AD and discusses risk stratification for oral JAK inhibitors in AD patients.
Get full access to this article
View all access options for this article.
References
1.
DamskyW, PetersonD, RamseierJ, et al.The emerging role of janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. J Allergy Clinical Immunol, 2021; 147(3):814–826.
2.
VerstovsekS, KantarjianH, MesaRA, et al.Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med, 2010; 363(12):1117–1127.
3.
VerstovsekS, MesaRA, GotlibJ, et al.A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med, 2012; 366(9):799–807.
4.
BerekmeriA, MahmoodF, WittmannM, et al.Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol, 2018; 14(9):719–730.
5.
MayenceA, Vanden EyndeJJ. Baricitinib: a 2018 novel FDA-approved small molecule inhibiting janus kinases. Pharmaceuticals (Basel), 2019; 12(1):37.
6.
RubinR.First systemic treatment for severe alopecia is approved. JAMA, 2022; 328(3):235–235.
NashP, KerschbaumerA, DörnerT, et al.Points to consider for the treatment of immune-mediated inflammatory diseases with janus kinase inhibitors: a consensus statement. Ann Rheum Dis, 2021; 80(1):71.
12.
BrunnerPM, Guttman-YasskyE, LeungDY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clinical Immunol, 2017; 139(4s):S65–s76.
13.
EgawaG, WeningerW. Pathogenesis of atopic dermatitis: a short review. Cogent Biol, 2015; 1(1):1103459.
14.
TaldaevA, RudnevVR, NikolskyKS, et al.Molecular modeling insights into upadacitinib selectivity upon binding to JAK protein family. Pharmaceuticals (Basel), 2021; 15(1):30.
15.
HowellMD, KuoFI, SmithPA. Targeting the janus kinase family in autoimmune skin diseases. Front Immunol, 2019; 10:2342–2342.
MorrisR, KershawNJ, BabonJJ. The molecular details of cytokine signaling via the JAK/STAT pathway. Protein Sci, 2018; 27(12):1984–2009.
18.
NeubauerH, CumanoA, MüllerM, et al.Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell, 1998; 93(3):397–409.
19.
NotarangeloLD, GilianiS, MazzaC, et al.Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency. Defects of the gamma(c)-JAK3 signaling pathway as a model. Immunol Rev, 2000; 178:39–48.
20.
TravesPG, MurrayB, CampigottoF, et al.JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis, 2021:annrheumdis-2020-219012.
21.
SheaJJ, KontziasA, YamaokaK, et al.Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis, 2013; 72(suppl 2):ii111.
22.
VainchenkerW, ConstantinescuSN. JAK/STAT signaling in hematological malignancies. Oncogene, 2013; 32(21):2601–2613.
ThaçiD, StroberB, GordonKB, et al.Deucravacitinib in moderate to severe psoriasis: clinical and quality-of-life outcomes in a phase 2 trial. Dermatol Ther (Heidelb), 2022; 12(2):495–510.
25.
SimpsonEL, LacourJP, SpelmanL, et al.Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol, 2020; 183(2):242–255.
26.
SilverbergJI, SimpsonEL, WollenbergA, et al.Long-term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials. JAMA Dermatol, 2021; 157(6):691–699.
BieberT, ReichK, PaulC, et al.Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance, or contraindication to cyclosporine: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). Br J Dermatol, 2022; 187(3):338–352.
29.
SimpsonEL, FormanS, SilverbergJI, et al.Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). J Am Acad Dermatol, 2021; 85(1):62–70.
30.
WollenbergA, NakaharaT, MaariC, et al.Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial. J Eur Acad Dermatol Venereol, 2021; 35(7):1543–1552.
31.
ReichK, KabashimaK, PerisK, et al.Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol, 2020; 156(12):1333–1343.
32.
ClinicalTrials.gov. A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis (BREEZE-AD-PEDS). 2019. Available at: https://clinicaltrials.gov/ct2/show/NCT03952559. Accessed July17, 2021.
33.
SimpsonEL, SinclairR, FormanS, et al.Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet, 2020; 396(10246):255–266.
34.
SilverbergJI, SimpsonEL, ThyssenJP, et al.Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol, 2020; 156(8):863–873.
35.
BieberT, SimpsonEL, SilverbergJI, et al.Abrocitinib versus placebo or dupilumab for atopic dermatitis. New Engl J Med, 2021; 384(12):1101–1112.
36.
Guttman-YasskyE, TeixeiraHD, SimpsonEL, et al.Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet, 2021; 397(10290):2151–2168.
BlauveltA, TeixeiraHD, SimpsonEL, et al.Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol, 2021; 157(9):1047–1055.
39.
SilverbergJI, GelfandJM, MargolisDJ, et al.Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol, 2018; 121(3):340–347.
40.
SilverbergJI.Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol, 2019; 123(2):144–151.
41.
NilssonJ, AnderssonMLE, HafströmI, et al.Influence of age and sex on disease course and treatment in rheumatoid arthritis. Open Access Rheumatol, 2021; 13:123–138.
42.
Avena-WoodsC.Overview of atopic dermatitis. Am J Manag Care, 2017; 23(8Suppl):S115–s123.
43.
EnglandBR, RoulP, YangY, et al.Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015. Ann Rheum Dis, 2021; 80(3):286–292; doi: 10.1136/annrheumdis-2020-218282
44.
RadnerH.Multimorbidity in rheumatic conditions. Wien Klin Wochenschr, 2016; 128(21–22):786–790.
45.
JackJD, McCutchanR, MaierS, et al.Polypharmacy in middle-european rheumatoid arthritis-patients: a retrospective longitudinal cohort analysis with systematic literature review. Front Med, 2020; 7:573542.
46.
ChovatiyaR, BegolkaWS, ThibauIJ, et al.Impact and associations of atopic dermatitis out-of-pocket health care expenses in the United States. Dermatitis, 2022; 33(6S):S43–S51; doi: 10.1097/DER.0000000000000795
47.
SinghP, SilverbergJ. Real-world outpatient prescription patterns for atopic dermatitis in the United States. Dermatitis, 2019; 30(5):294–299.
48.
NarlaS, SilverbergJI. Association between childhood atopic dermatitis and cutaneous, extracutaneous and systemic infections. Br J Dermatol, 2018; 178(6):1467–1468.
49.
KremerJM, BinghamCO, 3rd, CappelliLC, et al.Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a united states-based rheumatoid arthritis registry. ACR Open Rheumatol, 2021; 3(3):173–184.
50.
European Medicine Agency. EMA Confirms Xeljanz to Be Used with Caution in Patients at High Risk of Blood Clots. Amsterdam, Netherlands: European Medicine Agency; 2019.
51.
XieW, XiaoS, HuangY, et al.Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials. Ther Adv Musculoskelet Dis, 2019; 11:1759720x19895492.
52.
SimpsonEL, SilverbergJI, NosbaumA, et al.Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol, 2021; 22(5):693–707.
53.
CurtisJR, LeeEB, KaplanIV, et al.Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis, 2016; 75(5):831–841.
54.
CohenSB, van VollenhovenRF, WinthropKL, et al.Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis, 2020; 80(3):304–311.
55.
Vallejo-YagüeE, WeilerS, BurdenAM. OP0237 thromboembolic safety profile of tofacitinib and baricitinib: an analysis of who vigibase. Ann Rheum Dis, 2020; 79(Suppl 1):150–150.
56.
BieberT, ThyssenJP, ReichK, et al.Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol, 2021; 35(2):476–485.
BlauveltA, SilverbergJI, LyndeCW, et al.Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol, 2022; 86(1):104–112; doi: 10.1016/j.jaad.2021.05.075
59.
NarlaS, SilverbergJI. Safety of oral janus kinase inhibitors in the treatment of moderate-to-severe atopic dermatitis. Dermatitis, 2023. [Epub Ahead of Print]; doi: 10.1089/derm.2022.29004.sna
60.
FragoulisGE, McInnesIB, SiebertS. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford), 2019; 58(Suppl 1):i43–i54.
